Solid Biosciences, Inc.

As of August 14, 2023, Solid Biosciences, Inc. is considered overvalued with a valuation grade of "does not qualify," a Price to Book Value of 1.20, a troubling ROE of -45.26%, and a 1-year stock return of -30.19%, significantly underperforming compared to its peers and the S&P 500.

As of June 17, 2025, the technical trend is neutral with mixed signals, showing mildly bullish indicators on the weekly MACD and KST, but bearish signals on the monthly KST and daily moving averages, resulting in no strong directional trend.

As of March 2022, the management team of Solid Biosciences, Inc. includes Ian Smith (Chairman), Ilan Ganot (CEO), and several independent directors: Matthew Arnold, Martin Freed, Robert Huffines, Adam Koppel, and Sukumar Nagendran.

Solid Biosciences, Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD). It has a market cap of $357.35 million and reported a net profit loss of $39 million as of March 2025.

As of Jun 18, Solid Biosciences, Inc. has a market capitalization of 357.35 million, with net sales of 0.00 million and a net profit of -139.68 million over the latest four quarters. The company reported shareholder's funds of 137.25 million and total assets of 188.66 million as of Dec 24.